Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

The company revealed that its wholly owned subsidiary, Cana Laboratories, has entered into a ten-year contract manufacturing agreement with Provident Pharmaceuticals, a specialty pharmaceutical ...